GSKure is an IP-based company that owns innovative proprietary GSK-3 peptide inhibitor drug candidates.
The company's Kure products are based on a novel design of compounds that target a unique region at the GSK-3 protein surface termed the substrate binding site. The substrate-competitive inhibitors (SCIs) show improved selectivity and low toxicity compared to traditional ATP-competitive inhibitors.
GSKures novel SCI strategy for drug design offers significant advantages for clinical practice. Professor Hagit Eldar-Finkelman of Tel Aviv University conducted pioneering studies in developing GSK-3 inhibitors and their therapeutic use in treating human disease.
Cumulative Funding Raised Over Time ($)
Employees Over Time
GSKure Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Feb 11, 2016
www.israel21c.org
Brainnovations graduates first class of neurotech startups